Evidence map›Paper›PMID 42521817›Full record

ArticleNature medicine2026

The genetic architecture of fibromyalgia across 2.5 million individuals.

Isabel Kerrebijn, Gyda Bjornsdottir, Keon Arbabi, Lea Urpa, Hele Haapaniemi, Gudmar Thorleifsson, Lilja Stefansdottir, Stephan Frangakis, Jesse Valliere, Lovemore Kunorozva and 48 more

Abstract read
In one paragraph

Article in Nature medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. A neurogenetic blueprint for fibromyalgia.Nature reviews. Rheumatology · 2026
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

58 authors.

Isabel KerrebijnLunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada.ORCID http://orcid.org/0000-0001-8894-250X
Gyda BjornsdottirAmgen deCODE Genetics, Reykjavik, Iceland.ORCID http://orcid.org/0000-0002-8100-0306
Keon ArbabiLunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada.ORCID http://orcid.org/0000-0003-3219-8835
Lea UrpaStanley Center for Psychiatric Research, Broad Institute, Cambridge, MA, USA.ORCID http://orcid.org/0000-0002-8712-3518
Hele HaapaniemiInstitute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland.
Gudmar ThorleifssonAmgen deCODE Genetics, Reykjavik, Iceland.ORCID http://orcid.org/0000-0003-4623-9087
Lilja StefansdottirAmgen deCODE Genetics, Reykjavik, Iceland.
Stephan FrangakisDepartment of Anesthesiology, University of Michigan Medical School, Ann Arbor, MI, USA.
Jesse ValliereStanley Center for Psychiatric Research, Broad Institute, Cambridge, MA, USA.
Lovemore KunorozvaCenter for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA.
Erik AbnerInstitute of Genomics, Estonian Genome Center, University of Tartu, Tartu, Estonia.ORCID http://orcid.org/0000-0002-6529-3161
Caleb JiLunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada.ORCID http://orcid.org/0009-0007-7459-7646
Markus KangurLunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada.
Bitten AagaardDepartment of Clinical Immunology, Aalborg University Hospital, Aalborg, Denmark.ORCID http://orcid.org/0000-0001-8306-1332
Henning BliddalThe Parker Institute, Copenhagen University Hospital Bispebjerg Frederiksberg, Copenhagen, Denmark.
Søren BrunakDepartment of Public Health, University of Copenhagen, Copenhagen, Denmark.ORCID http://orcid.org/0000-0003-0316-5866
Mie T BruunClinical Immunology Research Unit, Department of Clinical Immunology, Odense University Hospital, Odense, Denmark.ORCID http://orcid.org/0000-0002-8819-5388
Maria DidriksenDepartment of Clinical Immunology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.ORCID http://orcid.org/0000-0002-4856-496X
Christian ErikstrupDepartment of Clinical Immunology, Aarhus University Hospital, Aarhus, Denmark.ORCID http://orcid.org/0000-0001-6551-6647
Sarah FinerWolfson Institute of Population Health, Queen Mary University of London, London, UK.ORCID http://orcid.org/0000-0002-2684-4653
Arni J GeirssonDepartment of Rheumatology, Landspitali University Hospital, Reykjavik, Iceland.
Daniel F GudbjartssonAmgen deCODE Genetics, Reykjavik, Iceland.
Thomas F HansenNeurogenomics, Translational Research Centre, Copenhagen University Hospital, Glostrup, Denmark.ORCID http://orcid.org/0000-0001-6703-7762
David van HeelBlizard Institute, Queen Mary University of London, London, UK.ORCID http://orcid.org/0000-0002-0637-2265
Ingileif JonsdottirAmgen deCODE Genetics, Reykjavik, Iceland.ORCID http://orcid.org/0000-0001-8339-150X
Stacey KnightIntermountain Medical Center, Intermountain Heart Institute, Salt Lake City, UT, USA.
Kirk U KnowltonIntermountain Medical Center, Intermountain Heart Institute, Salt Lake City, UT, USA.ORCID http://orcid.org/0000-0003-3544-4130
Christina MikkelsenDepartment of Clinical Immunology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.ORCID http://orcid.org/0000-0002-2945-6197
Lincoln D NadauldIntermountain Healthcare, Saint George, UT, USA.
Thorunn A OlafsdottirAmgen deCODE Genetics, Reykjavik, Iceland.
Sisse R OstrowskiDepartment of Clinical Immunology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.ORCID http://orcid.org/0000-0001-5288-3851
Ole B V PedersenDepartment of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.ORCID http://orcid.org/0000-0003-2312-5976
Saedis SaevarsdottirAmgen deCODE Genetics, Reykjavik, Iceland.
Astros T SkuladottirAmgen deCODE Genetics, Reykjavik, Iceland.
Erik SørensenDepartment of Clinical Immunology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
Hreinn StefanssonAmgen deCODE Genetics, Reykjavik, Iceland.ORCID http://orcid.org/0000-0002-9331-6666
Patrick SulemAmgen deCODE Genetics, Reykjavik, Iceland.
Olafur A SveinssonSchool of Health Sciences, Faculty of Medicine, University of Iceland, Reykjavik, Iceland.
Gudny E ThorlaciusAmgen deCODE Genetics, Reykjavik, Iceland.
Unnur ThorsteinsdottirAmgen deCODE Genetics, Reykjavik, Iceland.
Henrik UllumStatens Serum Institut, Copenhagen, Denmark.
Arnor VikingssonDepartment of Rheumatology, Landspitali University Hospital, Reykjavik, Iceland.
Thomas M WergeDepartment of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Chronic Pain Genomics Consortium
FinnGen
DBDS Genomic Consortium
Estonian Biobank Research Team
Genes & Health Research Team
Richa SaxenaCenter for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA.
Kari StefanssonAmgen deCODE Genetics, Reykjavik, Iceland.
Chad M BrummettDepartment of Anesthesiology, University of Michigan Medical School, Ann Arbor, MI, USA.
Bente GlintborgDepartment of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Daniel J ClauwChronic Pain and Fatigue Research Center, Department of Anesthesiology, University of Michigan, Ann Arbor, MI, USA.
Thorgeir E ThorgeirssonAmgen deCODE Genetics, Reykjavik, Iceland.
Frances M K WilliamsDepartment of Twin Research and Genetic Epidemiology, School of Life Course Sciences, King's College London, London, UK.ORCID http://orcid.org/0000-0002-2998-2744
Nasa Sinnott-Armstrong *Herbold Computational Biology Program, Fred Hutchinson Cancer Center, Seattle, WA, USA. nasa@fredhutch.org.ORCID http://orcid.org/0000-0003-4490-0601
Hanna M Ollila *Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA. hanna.m.ollila@helsinki.fi.ORCID http://orcid.org/0000-0002-5302-6429
Michael Wainberg *Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada. wainberg@lunenfeld.ca.ORCID http://orcid.org/0000-0001-6061-0239

Funding

Technology to understand genetic variant effects in contextRM1HG010461 · NHGRI · UNIVERSITY OF WASHINGTON · PI Douglas M Fowler, Bruce Colston Trapnell · 2019 to 2026
$18.9M
Genetic Markers of Chronic Postsurgical PainK08AR082454 · NIAMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Stephan Frangakis · 2023 to 2026
$697k
EC | Horizon 2020 Framework Programme (EU Framework Programme for Research and Innovation H2020) 101137154EC | Horizon 2020 Framework Programme (EU Framework Programme for Research and Innovation H2020) 101137201EC | Horizon 2020 Framework Programme (EU Framework Programme for Research and Innovation H2020) 894987European Commission (EC) H2020-2020-848099Gouvernement du Canada | Instituts de Recherche en Santé du Canada | CIHR Skin Research Training Centre (Skin Research Training Centre) FBD-199459Gouvernement du Canada | Instituts de Recherche en Santé du Canada | CIHR Skin Research Training Centre (Skin Research Training Centre) MHP-192163Ministry of Education and Research | Estonian Research Competency Council (Research Competency Council) PRG1291Natur og Univers, Det Frie Forskningsråd (Natural Sciences, Danish Council for Independent Research) 09-069412NHGRI NIH HHS RM1 HG010461NIAMS NIH HHS K08 AR082454Novo Nordisk Fonden (Novo Nordisk Foundation) NNF14CC0001Novo Nordisk Fonden (Novo Nordisk Foundation) NNF17OC0027594Novo Nordisk Fonden (Novo Nordisk Foundation) NNF17OC0027864Novo Nordisk Fonden (Novo Nordisk Foundation) NNF23OC0082015Oak Foundation OFIL-24-074U.S. Department of Health & Human Services | National Institutes of Health (NIH) K08AR082454U.S. Department of Health & Human Services | National Institutes of Health (NIH) RM1HG010461
6 · The paper itself

Abstract

Fibromyalgia is a common and debilitating chronic pain syndrome of poorly understood etiology. Here we conduct a multi-ancestry genome-wide association study meta-analysis across 2,563,755 individuals (54,629 cases and 2,509,126 controls) from 11 cohorts, identifying 26 risk loci for fibromyalgia. The strongest association was with a coding variant in HTT, the causal gene for Huntington's disease. Gene prioritization implicated the HTT regulator GPR52, as well as diverse genes with neural roles, including DCC, DRD2/NCAM1, MDGA2 and CELF4. Fibromyalgia heritability was exclusively enriched within brain tissues and neural cell types. Fibromyalgia showed strong, positive genetic correlation with a wide range of chronic pain, psychiatric and somatic disorders, including genetic correlations above 0.7 with low back pain, post-traumatic stress disorder and irritable bowel syndrome. Despite large sex differences in fibromyalgia prevalence, the genetic architecture of fibromyalgia was nearly identical between males and females. This study provides robust genetic evidence defining fibromyalgia as a central nervous system disorder, thereby establishing a biological framework for its complex pathophysiology and extensive clinical comorbidities.

Indexed as

FibromyalgiaGenetic Predisposition to DiseaseFemaleGenome-Wide Association StudyHumansMalePolymorphism, Single NucleotideStress Disorders, Post-Traumatic

Identifiers

PMID42521817
PMCPMC13472937

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.